New study tests if All-Keyhole surgery beats hybrid approach for esophageal cancer

NCT ID NCT07408999

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial will compare two surgical techniques for esophageal cancer: totally minimally invasive esophagectomy (TMIE) using only keyhole incisions, versus a hybrid approach that combines keyhole and open chest surgery. The study aims to see if TMIE reduces severe complications after surgery. About 327 adults with resectable esophageal or gastroesophageal junction cancer will take part across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Totally Minimally Invasive Esophagectomy (TMIE) - a surgical procedure using thoracoscopy instead of open chest surgery

What this could lead to

If TMIE proves better, it could become the new standard surgical approach for esophageal cancer, leading to fewer severe complications and faster recovery.

What could go wrong

This is a surgical technique comparison, not a new drug or cure. The trial is not yet recruiting, and results may show no significant difference between the two approaches.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal adenocarcinoma esophageal cancer esophageal squamous cell carcinoma gastroesophageal cancer gastroesophageal junction adenocarcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU de Lille

    Lille, 59037, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••